Lenalidomide Reddy Pharma

Lenalidomide, the active ingredient in Lenalidomide Reddy Pharma, is an immunomodulatory imide drug (IMiD) presented as an oral dosage form for oral use. Originating from the European Union market, it is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Reddy Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. - Mantle Cell Lymphoma: contributes to disease control in patients with relapsed or refractory mantle‑cell lymphoma.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often occurring after dosing. - Rash: mild skin eruptions or itching. - Constipation: reduced bowel movements causing discomfort. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Pregnancy loss: fetal toxicity leading to miscarriage.

When prescribing Lenalidomide, clinicians should observe several safety precautions. - Pregnancy contraindication: avoid use in pregnancy due to teratogenic risk (Category X). - Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: adjust therapy in patients with reduced kidney function. - Hepatic dysfunction: monitor liver function tests regularly. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide has several drug interaction considerations that can affect efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increase risk of bleeding when combined with lenalidomide‑associated thrombocytopenia. - Immunosuppressants (cyclosporine, tacrolimus): may enhance immunosuppressive effects.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors: can increase plasma concentrations. - NSAIDs: may exacerbate gastrointestinal irritation. - Vaccines (live attenuated): reduced efficacy due to immunomodulation.